A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma.

Trial Profile

A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Results of pooled analysis of two phase IV and II trials (NCT01731886 and NCT00807599) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Jul 2015 Planned number of patients changed from 114 to 60 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top